Clinical Trials Logo

Stage I Lung Cancer AJCC v8 clinical trials

View clinical trials related to Stage I Lung Cancer AJCC v8.

Filter by:

NCT ID: NCT03819296 Recruiting - Clinical trials for Malignant Solid Neoplasm

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Start date: February 21, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of the intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on cells, and help doctors understand how well patients respond to treatment. Treatment with fecal transplantation may help to improve diarrhea and colitis symptoms.

NCT ID: NCT03634241 Recruiting - Clinical trials for Lung Non-Small Cell Carcinoma

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Start date: November 13, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in preventing lung cancer patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.